Date: Wednesday 10 September 2014 - Thursday 11 September 2014

Location: London, UK

Related categories: Healthcare »

The use of biomarkers has become an important part of overall clinical development strategy for many pharmaceutical companies and CROs. The pathway from discovery to application in a commercially run clinical trial presents many scientific and administrative challenges. How is the value of a biomarker measured? What can be done to encourage more standardisation in biomarker development? How could a biomarker compromise the legitimacy of a clinical trial?       

The ACI Biomarker Utilisation & Commercialisation conference will explore the value of biomarkers from both a clinical and commercial perspective. The aim is to help end-users to develop a comprehensive strategy for biomarker discovery, development, application and analysis in clinical trials.

* Attendees will get to meet renowned experts in biomarkers to discuss and debate key issues. All this takes place in a friendly environment designed to encourage networking between participants. *

Topics on the Agenda

Benefit from an instructive two-day programme that explores a range of clinical and commercial factors affecting decision-makers in the world of biomarkers, combined with the opportunity for interaction with key opinion leaders.

Presentation Topics Include:

* Creating and Capturing Value with Biomarkers *
* Innovative Commercialisation of Companion Diagnostic Solutions *
* The Use of Human Genetics to Identify Novel Biomarkers for Clinical Trials *
* Biomarker Discovery to Diagnostic Development: What are the Challenges? *
* Applying Imaging Biomarkers to Reduce Risk in Drug Development *
* Intellectual Property Protection for Biomarker Utilisation *
* Biomarkers in Personalised Medicine: From Discovery to Repositioning *
* Statistical Innovations in Biomarker Utilisation *

Confirmed Speakers

Stephen Pennington, Professor of Proteomics, University College Dublin

Ciara Vangjeli, Applied Geneticist, Pfizer

Michael Boettcher, Global Clinical Project Leader, Bayer Schering Pharma

Linda Fellmann, International Product Manager, Companion Diagnostics, Roche Diagnostics

Peter Groenen, Head of Translational Science, Actelion

Markus Beier, European Patent Attorney, Comprehensive Biomarker Center GmbH

Alain van Gool, Head of Biomarkers in Personalized Healthcare, TNO

Alex Zhavoronkov, Director, Biogerontology Research Foundation

Yoshiya Oda, President, Biomarkers and Personalized Medicine, Eisai

Sterghios Moschos, Director, Westminster Genomic Services

Dr Richard Williams, Partner, HGF Limited

Dean Griffiths, Medical Technology Expert , Cambridge Consultants

Stephen R. Pennington, Professor of Proteomics, University College Dublin

Nick Baker, Technical Manager, Lloyd’s Register Quality Assurance (LRQA)

Athula Herath, Statistical Director, MedImmune

Dolores Cahill, Professor of Translational Science, University College Dublin

Kevin Cox, CEO, Imanova

Who Should Attend?

Heads, Managers, Directors, Associates, Leads and other professionals working in the following areas:

• Research and Development
• Clinical Trial Management
• Biomarker Discovery/Development
• Diagnostics
• Personalised medicine
• Regulatory Affairs
• Data Management
• Pricing and Reimbursement

For More Information on this Event or to Register, Contact:

Claire Taylor-Payne

Tel: +44 (0)20 3141 0601

Email: claire@acieu.net

For Information on Sponsorship and Commercial Opportunities, Contact:

Qam Raza

Tel: +44 (0)20 3141 0610

Email: qraza@acieu.net

If You Are Interested in Speaking at This Event, Contact:

Chris Taylor

Tel: +44 (0)20 3141 0602

Email: ctaylor@acieu.net

Conference Venue

London Marriott Regents Park

128 King Henry's Rd
London NW3 3ST

 

Media partners